Good morning and welcome to the ZyVersa Therapeutics 2024 annual stockholder meeting. My name is Steven Glover. I am Chief Executive Officer, President, and Chairman of the Board of Directors of ZyVersa Therapeutics. I'm pleased that you could join us today. This meeting is being held virtually to enable shareholders to attend regardless of their location. As is our custom, we will conduct the business portion of the meeting first and answer questions at the end of the meeting if time permits. Please keep in mind that we are not at liberty to share any material non-public information. This meeting is officially called to order, and the polls are now open. You may vote online prior to the closing of the polls in accordance with the proxy information you received prior to the meeting. I am pleased to introduce the other members of our board: Robert Finizio, Chairperson of our Compensation Committee and Member of our Audit Committee. Gregory Freitag, Chairperson of our Audit Committee and Member of our Nominating and Corporate Governance Committee. James Saperstein, Chairperson of our Nominating and Corporate Governance Committee and Member of our Audit and Compensation Committees. And Dr. Minchul Park, who is a member of our Compensation and Nominating and Corporate Governance Committees. I would also like to introduce our management team: Peter Wolf, Chief Financial Officer and Corporate Secretary. Dr. Pablo Guzman, Chief Medical Officer. And Karen Cashmere, Chief Commercial Officer. I will now turn the meeting over to Peter Wolf, who will act as Secretary of this meeting. Peter. Thanks, Steve. We are joined here today by our independent auditor, Marcum LLP, represented by one of the partners, Nina Guagliano, and our legal counsel, Thompson Hine LLP, represented by one of the partners, Faith Charles. I would like to announce that Marlene Aguilar, a representative of Broadridge Financial Solutions, has been appointed to act as Inspector of Elections. Ms. Aguilar's role is to verify the voter qualifications, accept their votes, and to tally the final votes. She has taken the oath of office to execute her duties with strict impartiality. We will now proceed with the formal business of the meeting, following which we will answer questions from stockholders time permitting. You may submit questions in the designated field on the web portal. I will now turn the meeting over to the Inspector of Elections. Marlene? Thank you. ZyVersa's Board of Directors fixed September 4, 2024, as the record date for determining stockholders entitled to vote at this meeting. An affidavit has been delivered attesting to the fact that all stockholders of record were sent information about internet availability of proxy materials and paper copies of the proxy materials were mailed to stockholders who requested them around September 9, 2024. Proxies have been received for 460,960 of the 1,074,196 shares of common stock outstanding and entitled to vote as of the record date. This represents approximately 43% of the total number of outstanding shares and constitutes a quorum for the meeting today. I will now turn the meeting back to Mr. Wolf, who will discuss the proposals for the vote. Thank you. There are four proposals to be considered by our stockholders. Proposal one is the election of one Class II Director nominee, Dr. Minchul Park, to hold office for a term of three years and until the nominee's successor is duly elected and qualified. Proposal two is ratification of the selection of our Audit Committee of Marcum LLP as our independent registered public accounting firm for the year ending December 31, 2024. Proposal three is approval of an amendment and restatement of our 2022 Omnibus Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 150,000 shares to a total of 181,795 shares. Proposal four is approval of the issuance of up to an aggregate of 478,600 shares of the company's common stock issuable upon the exercise of certain warrants to purchase the company's common stock in accordance with Nasdaq Listing Rule 5635(d). I will now turn the meeting back over to CEO Steven Glover. Thank you, Peter. The polls remain open to vote on each of the four proposals. This is the last call to submit your ballot. Any stockholder who hasn't yet voted or wishes to change their vote may do so by clicking on the voting button on the web portal and following the instructions provided there. Stockholders who have sent in proxies or voted via telephone or internet and do not want to change their vote do not need to take any further action. Each share of ZyVersa common stock is entitled to one vote. We will now pause to enable final voting. Now that everyone has had an opportunity to vote, I declare that the polls are closed on all proposals. Our Inspector of Elections will now announce the preliminary vote results. Marlene? Thank you. The preliminary vote report shows that Proposal One, to elect one nominee to the board, is approved. Proposal Two, to ratify the company's independent public accounting firm, is approved. Proposal Three, to increase the number of shares of common stock reserved for issuance under the company's incentive plan, is approved, and Proposal Four, to increase the number of shares of common stock issuable upon the exercise of certain warrants, is also approved. ZyVersa CEO will now adjourn the annual meeting and respond to any questions. Thank you, Marlene. ZyVersa will report the final vote results in a Form 8-K to be filed within four business days. There being no further business, the annual meeting of stockholders of ZyVersa Therapeutics is now adjourned. At this time, we're offering any stockholders and attendees the opportunity to ask questions, bearing in mind that we are not at liberty to share any material non-public information. Please note we will attempt to answer as many questions as time allows. You may submit questions in the designated field on the web portal. As there are no further questions, this concludes our meeting. Thank you for attending today. We appreciate your continued support.